POXEL.PA up 68% to €0.39 on PXL770 sale: Poxel (EURONEXT) volume spike Mar 2026

POXEL.PA stock led high-volume moves on EURONEXT today after Poxel S.A. reported an asset sale that pushed the share to €0.387, up 68.26% on heavy turnover. The rally showed 5,662,750.00 shares traded versus a 50-day average of 255,940.00, flagging a major liquidity event in Europe’s biotech space. Market closed with intraday high €0.406 and broader healthcare peers mixed, leaving traders focused on near-term funding and partnership impact.

POXEL.PA stock price action

The market moved decisively: POXEL.PA closed at €0.387 after opening at €0.23, a +€0.157 change and +68.26% intraday gain. Day range was €0.23–€0.406 and the 52-week range is €0.177–€0.83.

Volume confirmed the move: 5,662,750.00 shares traded versus average volume 255,940.00, giving a relative volume of 22.13. That volume spike marks this name as a high-volume mover on EURONEXT and explains the sudden price re-rating.

Catalyst: PXL770 sale details and immediate impact

Poxel announced the sale of PXL770 to SCYNEXIS, triggering an $8.0 million upfront payment plus up to $188.0 million in milestones. The deal includes potential commercial payments up to $180.0 million tied to sales thresholds and development milestones.

The market priced the asset monetization and the near-term cash runway improvement into POXEL.PA stock, prompting the heavy volume. For fuller deal terms see the company release and coverage: Poxel Business Wire release and trading context on Investing.com.

Fundamentals and valuation review

Key financials show a small market cap with stretched balance metrics: market capitalization €20,767,699.00, EPS -€0.26, and reported PE -1.49. Price-to-sales sits at 1.61 while enterprise value is €71,273,560.00, producing EV/sales of 9.31.

Liquidity and solvency remain constraints: current ratio 0.26 and cash per share €0.04 indicate tight near-term liquidity despite the sale proceeds. Investors should weigh the cash inflow from the asset sale against ongoing R&D burn and potential dilution.

Meyka AI grade and model summary

Meyka AI rates POXEL.PA with a score out of 100: 68.31 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

This grade is informational only; these grades are not guaranteed and we are not financial advisors. Meyka AI’s assessment highlights opportunity from the PXL770 sale but flags balance-sheet and execution risks for biotech peers in Europe.

Technical outlook and trading signals

Momentum reads near oversold-to-neutral: RSI 36.55 and CCI -152.53, while short-term moving average sits at €0.26816 (50-day) and long-term at €0.34006 (200-day). Price is above the 50-day average but roughly in line with the 200-day average.

The trade shows momentum with heavy volume and an on-balance-volume build; short-term traders may look for follow-through above €0.40, while failure to hold €0.23 opens rapid downside given low float and tight book metrics.

Forecasts, price targets and risk view

Meyka AI’s forecast model projects a near-term monthly target of €0.59, a quarterly projection of €0.56, and a one-year projection of €0.30. Compared with the current price of €0.387, the monthly target implies an upside of +52.48%, while the one-year projection implies -22.12% downside.

Forecasts are model-based projections and not guarantees. Upside depends on milestone receipts from the SCYNEXIS deal, clinical progress for remaining assets, and the company’s ability to secure non-dilutive funding or partnerships.

Final Thoughts

POXEL.PA stock moved to the top of high-volume movers on EURONEXT after the PXL770 sale to SCYNEXIS drove a liquidity event and heavy trading. The share closed at €0.387 with 5,662,750.00 shares traded, far above the average of 255,940.00, confirming market re-pricing. Fundamentals remain stretched — EPS -0.26, current ratio 0.26, and market cap €20.77m — so the rally largely prices deal value and optionality rather than steady cash flow. Meyka AI’s forecast model projects a near-term monthly target of €0.59, implying +52.48% from today’s price; the one-year model sits at €0.30, implying -22.12%. These divergent projections underline uncertainty: upside is tied to milestone payments and partner execution, while downside reflects cash runway and biotech execution risk. Use tight risk management on any position and monitor official milestone receipts and updates on TWYMEEG® and PXL065 programs. Meyka AI provides this as an AI-powered market analysis platform and stresses forecasts are model-based projections and not guarantees. For company filings and the full deal text see the Business Wire release and market pages on Investing.com, and for trading context visit our internal note at Poxel on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.